Leqembi IV maintenance dosing approved in China

Japanese drugmaker Eisai (TYO: 4523) and US biotech major Biogen’s (Nasdaq: BIIB) humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China.

In January 2024, Leqembi was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease - collectively referred to as early AD - in China. 

After 18 months of a dosing regimen of 10mg/kg once every two weeks during initiation phase, a transition to the maintenance dosing regimen of 10mg/kg once every four weeks may be considered, or the regimen of 10 mg/kg once every two weeks may be continued.